Carlos Galvez
Overview
Explore the profile of Carlos Galvez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
"Complex segmentectomies: Comparison with simple and effect of experience on postoperative outcomes"
Galvez C, Bolufer S, Lirio F, Recuero J, Corcoles J, Socci L, et al.
Eur J Surg Oncol
. 2025 Mar;
51(7):109748.
PMID: 40064065
Objectives: We compared simple and complex segmentectomies in terms of complications and mortality. We hypothesized which proportion of complex segmentectomies might improve postoperative outcomes. Methods: Patients from 18 hospitals operated...
2.
Rubinstein P, Galvez C, Ambinder R
Curr Opin Infect Dis
. 2024 May;
37(4):254-263.
PMID: 38820072
Purpose Of Review: Summarize the latest research of both stem cell transplantation and cellular therapy and present the implications with respect to persons with HIV (PWH), hematologic malignancies, and HIV-1...
3.
Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia
Palmer A, Rauscher G, Abraham I, Burkart M, Dave A, Raptis N, et al.
Blood Adv
. 2024 May;
8(17):4647-4650.
PMID: 38810264
No abstract available.
4.
Nickles M, Hunt S, Turcios-Escobar S, Babwah A, Mobayed N, Murga-Zamalloa C, et al.
Am J Dermatopathol
. 2024 Apr;
46(7):443-446.
PMID: 38648045
Richter syndrome (RS) describes a phenomenon in which a patient with chronic lymphocytic leukemia (CLL) develops an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). Reports of cutaneous RS...
5.
Tran S, Lin J, Galvez C, Rasmussen L, Pacheco J, Perottino G, et al.
Front Immunol
. 2024 Apr;
15:1331959.
PMID: 38558818
Introduction: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) poses a major clinical challenge to ICI therapy for cancer, with 13% of cases halting ICI therapy and ICI-IA being difficult to identify...
6.
Karmali R, Galvez C, Hamadani M, Gordon L, Winter J, Ma S, et al.
Blood Adv
. 2024 Jan;
8(7):1612-1620.
PMID: 38237077
MYC-aberrant non-Hodgkin lymphoma (NHL) is associated with poor outcomes with conventional chemotherapy. Ixazomib is an orally bioavailable proteasome inhibitor that targets drivers of MYC expression and has demonstrated preclinical activity...
7.
Karampinis I, Ruckes C, Doerr F, Bolukbas S, Ricciardi S, Cardillo G, et al.
Trials
. 2024 Jan;
25(1):20.
PMID: 38166982
Background: The prolonged air leak is probably the most common complication following lung resections. Around 10-20% of the patients who undergo a lung resection will eventually develop a prolonged air...
8.
Del Campo J, Maroto S, Sebastian L, Vaillo X, Bolufer S, Lirio F, et al.
Diagnostics (Basel)
. 2023 Mar;
13(5).
PMID: 36899970
Uniportal VATS has become an accepted approach in minimally invasive thoracic surgery since its first report for lobectomy in 2011. Since the initial restrictions in indications, it has been used...
9.
Elkhouly A, Karamustafaoglu Y, Galvez C, Rao M, Lerut P, Grimonprez A, et al.
Asian Cardiovasc Thorac Ann
. 2022 Sep;
30(9):1010-1016.
PMID: 36163699
Background: We aimed at comparing in a multicenter propensity-matched analysis, results of nonintubated versus intubated video-assisted thoracic surgery (VATS) bullectomy/blebectomy for primary spontaneous pneumothorax (PSP). Methods: Eleven Institutions participated in...
10.
Zurko J, Nizamuddin I, Epperla N, David K, Cohen J, Moyo T, et al.
Blood Adv
. 2022 Sep;
7(12):2657-2669.
PMID: 36094847
Most patients receiving chimeric antigen receptor T-cell therapy (CAR-T) for aggressive B-cell non-Hodgkin lymphoma (B-NHL) do not experience a durable remission. Several novel agents are approved to treat relapsed, refractory...